• Niagen Bioscience won FDA Rare Pediatric Disease designation for NB4168 to treat ataxia-telangiectasia.
• EMA granted orphan medicinal product designation for NB4168, supporting global clinical development incentives for the rare genetic disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713674314) on July 13, 2026, and is solely responsible for the information contained therein.